Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Petsinis et al. [7] 2017 RS 2/5 GCAb 0/2 Mean: 47.5 100% (2/2)
100% (5/5) 		100% (2/2)
NR 		NR 0% (0/2)
0% (0/5) 		NR
1/2 PNb 1/0 48 100% (1/1)
100% (2/2) 		100% (1/1)
NR 		NR 0% (0/1)
0% (0/2) 		NR
Bencharit et al. [33] 2010 CR 1/12 PR (without GCA) 0/1 19 100% (1/1)
100% (12/12) 		NR NR NR NR
Li et al. [51] 2004 CR 1/5 MCTD+SLE 0/1 36 100% (1/1)
100% (5/5) 		100% (1/1)
NR 		NR NR NR
Payne et al. [81] 1997 CS 1/8 ST+sSS 0/1 12 100% (1/1)
100% (8/8) 		100% (1/1)
100% (2/2) 		NR NR NR
Overall
Other autoimmune CTDs - CR: 2
CS: 1
RS: 1 		6/32 - Ratio: 1/5 Mean: 35 100% (6/6)
100% (32/32) 		100% (5/5)
100% (2/2) 		NR 0% (0/3)
0% (0/7) 		NR
Other autoimmune CTDs
+concomitant ADs 		- CR: 1
CS: 1 		2/13 - Ratio: 0/2 Mean: 24 100% (2/2)
100% (13/13) 		100% (2/2)
100% (2/2) 		NR NR NR

a = weighted mean or median; b = remission at implant placement.
ADs = autoimmune diseases; CR = case report; CS = case series; GCA = giant cell arteritis; M/F = male/female; MCTD = mixed connective tissue disease; N = number; NR = not reported; PI = peri-implantitis; PN = polyarteritis nodosa; PR = polymyalgia rheumatica; RS = retrospective study; SLE = systemic lupus erythematosus; sSS = secondary Sjögren's syndrome; ST = Still's disease.